SCHEMBL4934586

SCHEMBL4934586

CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1C

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 13/20 0.74
CYP3A4 P08684 6/20 0.74
CYP2D6 P10635 6/20 0.74
RPS6KB1 P23443 3/20 0.74
RPS6KA1 Q15418 3/20 0.74
CYP2C9 P11712 2/20 0.74
ROCK2 O75116 1/20 0.39
ACACB O00763 1/20 0.37
ACACA Q13085 1/20 0.37
MAOB P27338 1/20 0.34
LRRK2 Q5S007 2/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
MAP4K4 O95819 1/20 0.33
CLK2 P49760 1/20 0.33
DYRK1A Q13627 1/20 0.33
SRPK1 Q96SB4 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620261 0.85 ROCK1 (1.00) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4932798 0.85 ROCK1 (1.00) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL30197895 0.80 ROCK1 (0.58) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4936335 0.79 ROCK1 (1.00) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4935013 0.77 ROCK1 (1.00) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4324693 0.77 ROCK1 (0.54) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4937845 0.76 ROCK1 (0.83) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4935272 0.76 ROCK1 (1.00) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4935363 0.75 ROCK1 (1.00) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4933911 0.73 ROCK1 (0.83) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125427-A1 Novel Inhibitors of Rho-Kinases SMITHKLINE BEECHAM CORPORATION (US) 2008-05-29 US claimed
US-20080125427-A1 Novel Inhibitors of Rho-Kinases SMITHKLINE BEECHAM CORPORATION (US) 2008-05-29 US disclosed
US-20080125427-A1 Novel Inhibitors of Rho-Kinases SMITHKLINE BEECHAM CORPORATION (US) 2008-05-29 US disclosed
US-20080125427-A1 Novel Inhibitors of Rho-Kinases SMITHKLINE BEECHAM CORPORATION (US) 2008-05-29 US disclosed
EP-1756092-A1 NOVEL INHIBITORS OF RHO-KINASES SMITHKLINE BEECHAM CORPORATION (US) 2007-02-28 EP disclosed
WO-2006009889-A1 NOVEL INHIBITORS OF RHO-KINASES SMITHKLINE BEECHAM CORPORATION (US) 2006-01-26 WO disclosed
WO-2006009889-A1 NOVEL INHIBITORS OF RHO-KINASES SMITHKLINE BEECHAM CORPORATION (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125427-A1 Novel Inhibitors of Rho-Kinases ROCK1, ARHGDIB, ARHGDIA ROCK1 1/4885CYP3A4 4789/4885CYP2D6 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.